PBRM1 and nonpapillary renal cell carcinoma: A meta-analysis that included 2942 patients reported that a lower PBRM1 expression level is correlated with a dismal prognosis, advanced clinical stage, and a higher Fuhrman nuclear grade in ccRCC as well as responsiveness to immune checkpoint inhibitors (103).